Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06713499
PHASE1/PHASE2
A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis
Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
View on ClinicalTrials.gov
Summary
This trial was designed to evaluate the safety of SHR-1819 in children and adolescents with moderate-to-severe atopic dermatitis.
Official title: A Phase Ib/II Study to Investigate the Safety、PK and PD of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis
Key Details
Gender
All
Age Range
6 Years - 18 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2024-12-18
Completion Date
2025-12
Last Updated
2025-07-10
Healthy Volunteers
No
Interventions
DRUG
SHR-1819 injection
SHR-1819 injection.
Locations (1)
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China